Stay updated with breaking news from Norbert Kraut. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: QUANTRO Therapeutics GmbH / Key word(s): Miscellaneous QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class
EQS-News: QUANTRO Therapeutics GmbH / Key word(s): MiscellaneousQUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments 04.06.2024 / 23:07 CET/CESTThe issuer is solely responsible for the content of this announcement.QUANTRO Therapeutics rea...
Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies - News - PharmaTimes
April 14, 2021 healthcare Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. ...
E-Mail HOUSTON and Ingelheim, Germany ? The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim's KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer. The collaboration, launched in 2019, has successfully combined MD Anderson's innovative clinical research infrastructure and the patient...